Rezultati pretraživanja
  1. 3. lip 2018.

    . Association of genotypes, clinical scores and survival outcomes in metastatic colorectal cancer. Dr. Joan Maurel.

  2. 4. lip 2018.

    Professor Conroy presents landmark trial of FOLFIRINOX v Gemcitabine this afternoon . FOLFIRINOX improves survival and is a new standard of care for patients following surgery for pancreatic cancer. A remarkable result.

  3. 4. lip 2018.

    Tom Gajewski discussing our data the potential of artificial intelligence to predict response to immunotherapy

  4. 3. lip 2018.

    Excellent presentation on cytoreductive nephrectomy in mRCC by Arnaud Mejean - clearly shows no need to do surgery on poor or intermediate risk patients.

  5. 3. lip 2018.

    Maintenance low dose chemotherapy in high-risk rhabdomyosarcoma improves overall survival.

  6. 3. lip 2018.

    . Great company at ASCO 2018 Chicago. .

  7. 5. lip 2018.

    Assessing IO response session on the last day of . Big commitment from attendees!

  8. 5. lip 2018.

    GOG277 closed early to low accrual but even with only small number of patients, no survival benefit to multiagent chemo for early stage leiomyosarcoma. Observation remains standard of care.

  9. 4. lip 2018.

    Global disparities in cancer survival: the most powerful message of # - we need to combine efforts on multiple fronts to tackle this. Training, education, funding, public health.

  10. 4. lip 2018.

    An inspiring presentation of up to date evidence-based -adjusted algorithm of advanced NSCLC TODAY by . Great to watch, great to be part of it

  11. 4. lip 2018.

    Huntingdon et al: Cost-effectiveness analysis showing AVD+BV is not cost-effective at current price - 40-60% price reduction would be needed to reduce cost per QALY to more acceptable levels (probably not there for NHS still though).

  12. 3. lip 2018.

    Proud to be presenting PRIMUS-001, 1st line metastatic trial in at Trial in Progress poster session

  13. Suboptimal Induction CT in Larynx-Hypofarynx squamous cell cancer independently linked to worse prognosis . Poster presented in by Miguel Servet Hospital from Spain.

  14. 4. lip 2018.

    Tonight I hugged my friend's mom & dad. My friend died of metastatic cancer last week. We all cried together as the line up behind us at the wake piled up. My husband shook her husband's hand knowing he was looking at his future. Thank you to every researcher at

  15. 5. lip 2018.

    This pathologist has loved following from afar via Twitter! Encourage my colleagues to connect with our partners in oncology & engage in the latest cancer treatment discussions... we can learn a lot from these conversations, and can add a lot to boot!

  16. 3. lip 2018.

    TAILORx study, >10,000 women recruited. Adjuvant endocrine therapy and CT-endocrine therapy similar efficacy in women with ER–positive, HER2-negative, axillary node–negative with a midrange recurrence score, BUT some benefit of CT was found in some women <50 yrs.

  17. 3. lip 2018.

    Informative and comprehensive talk by from about how to incorporate tumor mutation analysis into care and clinical trials in Gyn oncology

  18. 5. lip 2018.

    Very interesting to note that a study which made it to the plenary aint influencing the algorithm

    Prikaži ovu nit
  19. 5. lip 2018.

    Seems like we are looking at the new SOC for elderly not-so-fit AML. The fit ones may do even better. And aza might be a better combo than 7+3, esp. for adv risk. A robust predictive biomarker would come handy. And kudos to for great tweets!

  20. 3. lip 2018.

    Dr. Stacy Moulder about to start education series. Delivering discoveries...

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.